Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known a… Read more
Cassava Sciences Inc (SAVA) - Net Assets
Latest net assets as of September 2025: $81.57 Million USD
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has net assets worth $81.57 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($129.73 Million) and total liabilities ($48.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $81.57 Million |
| % of Total Assets | 62.87% |
| Annual Growth Rate | 11.71% |
| 5-Year Change | 58.03% |
| 10-Year Change | 396.15% |
| Growth Volatility | 171.58 |
Cassava Sciences Inc - Net Assets Trend (1999–2024)
This chart illustrates how Cassava Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cassava Sciences Inc (1999–2024)
The table below shows the annual net assets of Cassava Sciences Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $145.70 Million | +5.99% |
| 2023-12-31 | $137.47 Million | -39.58% |
| 2022-12-31 | $227.54 Million | -10.39% |
| 2021-12-31 | $253.91 Million | +175.40% |
| 2020-12-31 | $92.20 Million | +317.21% |
| 2019-12-31 | $22.10 Million | +12.59% |
| 2018-12-31 | $19.63 Million | +102.37% |
| 2017-12-31 | $9.70 Million | -47.96% |
| 2016-12-31 | $18.64 Million | -36.54% |
| 2015-12-31 | $29.37 Million | -26.69% |
| 2014-12-31 | $40.06 Million | -17.07% |
| 2013-12-31 | $48.30 Million | +267.71% |
| 2012-12-31 | $13.14 Million | -70.41% |
| 2011-12-31 | $44.39 Million | +34.80% |
| 2010-12-31 | $32.93 Million | -69.58% |
| 2009-12-31 | $108.25 Million | +3.80% |
| 2008-12-31 | $104.29 Million | +0.36% |
| 2007-12-31 | $103.91 Million | +33.37% |
| 2006-12-31 | $77.92 Million | +22.97% |
| 2005-12-31 | $63.36 Million | -32.16% |
| 2004-12-31 | $93.40 Million | +21.99% |
| 2003-12-31 | $76.56 Million | +52.44% |
| 2002-12-31 | $50.22 Million | -23.46% |
| 2001-12-31 | $65.62 Million | -16.62% |
| 2000-12-31 | $78.69 Million | +760.94% |
| 1999-12-31 | $9.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cassava Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40022240800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.03% |
| Other Components | $550.77 Million | 378.00% |
| Total Equity | $145.70 Million | 100.00% |
Cassava Sciences Inc Competitors by Market Cap
The table below lists competitors of Cassava Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Manitex International Inc
NASDAQ:MNTX
|
$86.46 Million |
|
Knowmerce
KQ:473980
|
$86.52 Million |
|
Xpro India Limited
NSE:XPROINDIA
|
$86.52 Million |
|
UNIMECH
NSE:UNIMECH
|
$86.53 Million |
|
Univacco Technology
TWO:3303
|
$86.41 Million |
|
Compagnie des Tramways de Rouen
PA:MLTRA
|
$86.41 Million |
|
EVA Precision Industrial Holdings Limited
F:GZT
|
$86.41 Million |
|
KlaraBo Sverige AB Series B
ST:KLARA-B
|
$86.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cassava Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 137,468,000 to 145,704,000, a change of 8,236,000 (6.0%).
- Net loss of 24,342,000 reduced equity.
- Other factors increased equity by 32,578,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.34 Million | -16.71% |
| Other Changes | $32.58 Million | +22.36% |
| Total Change | $- | 5.99% |
Book Value vs Market Value Analysis
This analysis compares Cassava Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.46x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.19 | $2.00 | x |
| 2000-12-31 | $22.57 | $2.00 | x |
| 2001-12-31 | $18.13 | $2.00 | x |
| 2002-12-31 | $13.00 | $2.00 | x |
| 2003-12-31 | $18.18 | $2.00 | x |
| 2004-12-31 | $17.54 | $2.00 | x |
| 2005-12-31 | $10.13 | $2.00 | x |
| 2006-12-31 | $11.99 | $2.00 | x |
| 2007-12-31 | $15.93 | $2.00 | x |
| 2008-12-31 | $16.65 | $2.00 | x |
| 2009-12-31 | $17.97 | $2.00 | x |
| 2010-12-31 | $5.41 | $2.00 | x |
| 2011-12-31 | $7.04 | $2.00 | x |
| 2012-12-31 | $2.05 | $2.00 | x |
| 2013-12-31 | $7.48 | $2.00 | x |
| 2014-12-31 | $6.19 | $2.00 | x |
| 2015-12-31 | $4.49 | $2.00 | x |
| 2016-12-31 | $2.86 | $2.00 | x |
| 2017-12-31 | $1.48 | $2.00 | x |
| 2018-12-31 | $1.84 | $2.00 | x |
| 2019-12-31 | $1.27 | $2.00 | x |
| 2020-12-31 | $3.53 | $2.00 | x |
| 2021-12-31 | $6.44 | $2.00 | x |
| 2022-12-31 | $5.66 | $2.00 | x |
| 2023-12-31 | $3.28 | $2.00 | x |
| 2024-12-31 | $3.13 | $2.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cassava Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-16.71%) is above the historical average (-26.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -49.23% | -449958500.00% | 0.00x | 1.03x | $-5.41 Million |
| 2000 | -22.21% | -1747979000.00% | 0.00x | 1.03x | $-25.35 Million |
| 2001 | -21.85% | 0.00% | 0.00x | 1.04x | $-20.90 Million |
| 2002 | -31.71% | -13969.30% | 0.00x | 1.06x | $-20.95 Million |
| 2003 | -28.23% | 0.00% | 0.00x | 1.05x | $-29.27 Million |
| 2004 | -40.45% | 0.00% | 0.00x | 1.08x | $-47.12 Million |
| 2005 | -48.41% | -603.74% | 0.02x | 3.41x | $-37.01 Million |
| 2006 | 7.94% | 11.48% | 0.26x | 2.68x | $-1.60 Million |
| 2007 | 19.54% | 30.77% | 0.32x | 2.00x | $9.91 Million |
| 2008 | 14.72% | 24.08% | 0.33x | 1.85x | $4.92 Million |
| 2009 | -3.20% | -16.86% | 0.11x | 1.68x | $-14.29 Million |
| 2010 | -36.51% | -71.53% | 0.17x | 3.01x | $-15.32 Million |
| 2011 | -5.89% | -22.75% | 0.12x | 2.23x | $-7.05 Million |
| 2012 | -26.23% | -31.64% | 0.19x | 4.33x | $-4.76 Million |
| 2013 | 65.31% | 76.71% | 0.82x | 1.04x | $26.71 Million |
| 2014 | -30.92% | 0.00% | 0.00x | 1.02x | $-16.39 Million |
| 2015 | -48.17% | 0.00% | 0.00x | 1.09x | $-17.08 Million |
| 2016 | -79.68% | 0.00% | 0.00x | 1.04x | $-16.71 Million |
| 2017 | -122.81% | 0.00% | 0.00x | 1.12x | $-12.88 Million |
| 2018 | -33.41% | 0.00% | 0.00x | 1.03x | $-8.52 Million |
| 2019 | -19.21% | 0.00% | 0.00x | 1.06x | $-6.45 Million |
| 2020 | -6.87% | 0.00% | 0.00x | 1.02x | $-15.55 Million |
| 2021 | -12.52% | 0.00% | 0.00x | 1.05x | $-57.19 Million |
| 2022 | -31.85% | 0.00% | 0.00x | 1.03x | $-95.23 Million |
| 2023 | -70.72% | 0.00% | 0.00x | 1.10x | $-110.96 Million |
| 2024 | -16.71% | 0.00% | 0.00x | 1.08x | $-38.91 Million |
Industry Comparison
This section compares Cassava Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cassava Sciences Inc (SAVA) | $81.57 Million | -49.23% | 0.59x | $86.43 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |